查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1738613

全球间质性膀胱炎药物市场规模（按类型、销售管道、区域范围和预测）

Global Interstitial Cystitis Drugs Market Size By Type (Oral Therapy, Intravesical Therapy), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

间质性膀胱炎治疗药物的市场规模及预测

间质性膀胱炎药物市场规模在 2024 年价值 3.5664 亿美元，预计到 2032 年将达到 5.0844 亿美元，2026 年至 2032 年的复合年增长率为 5.00%。

间质性膀胱炎的高发生率推动了全球间质性膀胱炎药物市场的发展。基因疗法的兴起对全球市场产生了正面影响。然而，这些药物价格昂贵，副作用较多。因此，越来越多的公司正在开发再生疗法和基因治疗方法等创新治疗方法，因为与市场上现有的传统仿单标示外药物相比，这些疗法副作用较少。全球间质性膀胱炎药物市场报告提供了市场的整体评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

全球间质性膀胱炎药物市场的定义

间质性膀胱炎 (IC)，通常称为疼痛性膀胱综合征，是一种慢性膀胱疾病，常表现为膀胱压迫感和疼痛，以及腰背部、骨盆和下腹部疼痛。患者可能会感到疼痛，程度从轻微到严重不等。当患有间质性膀胱炎时，骨盆神经向大脑发出的讯号会混淆。因此，会出现尿急，但尿量通常很少。平均而言，一个人每天排尿七次，但在严重的 IC 病例中，每天排尿次数可达 40 至 60 次。虽然 IC 不是感染疾病，但它经常被误认为是膀胱炎。间质性膀胱炎是由膀胱上皮层缺陷引起的，导致尿液洩漏并使尿液中的有害物质刺激膀胱壁。

口服和膀胱内治疗分别是治疗间质性膀胱炎的首选和次级方案。然而，没有一种治疗方法对所有患者都有效。治疗方案取决于每位患者的症状。为了消除症状，大多数患者会尝试各种治疗方法（或多种治疗方法的组合）。目前，只有两种药物被核准用于治疗间质性膀胱炎：Elmiron 和 RIMSO-50（二甲基亚砜）。这些药物已被证明比对症治疗更有效。然而，这些药物的价格很高。因此，许多患者主要服用仿单标示外药物来缓解疾病症状。

间质性膀胱炎药物全球市场概况

间质性膀胱炎的高发生率推动了全球间质性膀胱炎药物市场的发展。基因疗法的出现对全球市场产生了正面影响。大多数核准仿单标示外列入药品说明书的间质性膀胱炎治疗药物均为小分子化合物，这些药物无法治癒疾病，对患者有副作用，而且价格昂贵。间质性膀胱炎患者会出现下泌尿道疾病和膀胱疼痛等症状。女性发病率较高。该疾病还伴随多种併发症，例如过敏、纤维肌痛和子宫内膜异位症。

间质性膀胱炎病例的不断增加推动了对间质性膀胱炎药物的需求。由于现有间质性膀胱炎药物的不足，各公司正在开发副作用较少的创新治疗方法，例如再生疗法和基因疗法。预计此类治疗方法的发展将推动需求成长。因此，间质性膀胱炎的高盛行率加上基因疗法的兴起，预计将在预测期内推动间质性膀胱炎药物市场规模的成长。

间质性膀胱炎的主要挑战在于，儘管有许多可用治疗方法，但缺乏普遍接受的治疗方法。药物未获得FDA核准是全球间质性膀胱炎药物市场发展的主要限制因素。然而，由于现有产品的疗效和依从性方面的限制，间质性膀胱炎药物市场目前处于疲软状态。核准治疗方案有限、缺乏相关知识、对缓解疾病疗法的需求是其他因素。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章调查方法

  • 资料探勘
  • 二次研究
  • 初步研究
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程

第三章执行摘要

  • 市场概览
  • 全球间质性膀胱炎药物市场按地区分析（CAGR）
  • 全球间质性膀胱炎药物市场（按类型）
  • 全球间质性膀胱炎药物市场（依分销管道）
  • 未来市场机会
  • 全球市场区隔

第四章 市场展望

  • 市场驱动因素
    • 美国间质性膀胱炎盛行率高
    • 活性化研究活动
  • 市场限制
    • 消费者缺乏意识、药品核准有限、治疗费用高昂
  • 市场机会
    • 再生医学和基因疗法等创新治疗方法的出现
  • COVID-19 对全球间质性膀胱炎药物市场的影响
  • 波特五力分析
  • 产品生命线

第五章 市场类型

  • 概述
  • 口服疗法
  • 膀胱内治疗

第六章 分销通路市场

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第七章 区域市场

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 其他亚太地区
  • 其他地区
    • 中东和非洲
    • 拉丁美洲

第八章竞争格局

  • 概述
  • 竞争场景
  • 企业市场排名分析

第九章 公司简介

  • PFIZER INC.
  • JOHNSON & JOHNSON
  • KYORIN PHARMACEUTICAL
  • UCB PHARMA
  • ASTELLAS PHARMA
  • ELI LILLY AND COMPANY
  • BAYER AG
  • LIPELLA PHARMACEUTICALS
  • SEIKAGAKU CORPORATION
  • GRUNENTHAL
Product Code: 62441

Interstitial Cystitis Drugs Market Size And Forecast

Interstitial Cystitis Drugs Market size was valued at USD 356.64 Million in 2024 and is projected to reach USD 508.44 Million by 2032, growing at a CAGR of 5.00% from 2026 to 2032.

The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Moreover, these drugs are expensive and cause many side effects. This is encouraging companies to establish innovative treatment options such as regenerative therapy and gene therapy as these drugs cause lesser side effects compared to the conventional off-label drugs already available in the market. The Global Interstitial Cystitis Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Interstitial Cystitis Drugs Market Definition

Interstitial cystitis (IC), commonly referred to as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, as well as occasional pain in the lower back, pelvis, or lower abdomen. The patient could experience pain ranging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume, is observed. On average, a person urinates seven times a day; however, in severe cases of IC, urination may occur around 40-60 times a day. IC is not an infection but is often mistaken to be a bladder infection. Interstitial cystitis is caused by a defect of the epithelium layer of the bladder, leaking epithelium allows toxic substances in urine to irritate the bladder wall.

Oral therapy and intravesical therapy are the first- and second-line choices for treating interstitial cystitis, respectively. However, no one treatment is effective for all patients. The course of treatment is determined by each patient's symptoms. To eliminate the symptoms, the majority of patients try various treatments (or treatment combinations). There are currently just two approved drugs for treating interstitial cystitis, ELMIRON, and RIMSO-50 (dimethyl sulfoxide). These drugs have been shown to be more effective than symptomatic treatments. But the price of these drugs is high. Therefore, a lot of patients take off-label drugs largely to relieve the symptoms of the disease.

Global Interstitial Cystitis Drugs Market Overview

The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Most of the approved and off-label drugs for interstitial cystitis are small molecules, which cannot completely cure the disease, have side effects on the patients, and are expensive. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. Numerous comorbidities, including allergies, fibromyalgia, and endometriosis, are linked to this condition.

The increasing number of interstitial cystitis cases is driving the demand for interstitial cystitis drugs. Owing to the disadvantages of available drugs for interstitial cystitis, companies are developing innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. The development of such therapies will drive demand. Thus, the high prevalence of interstitial cystitis coupled with the advent of gene therapy will drive the Interstitial Cystitis Drugs Market size growth during the forecast period.

The major challenge for Interstitial Cystitis is that though there are several types of treatment available, no one treatment is universally acceptable. The lack of FDA approval for drugs is a major restraining factor for the Global Interstitial Cystitis Drugs Market. However, the Interstitial Cystitis Drugs Market is currently weak owing to limitations regarding the efficacy and compliance of available products. Limited approved treatment options, a lack of knowledge, and the demand for disease-modifying treatments are additional factors.

Global Interstitial Cystitis Drugs Market Segmentation Analysis

The Global Interstitial Cystitis Drugs Market is segmented on the basis of Type, Sales Channel, and Geography.

Interstitial Cystitis Drugs Market, By Type

  • Oral Therapy
  • Intravesical Therapy

Based on Type, the market is bifurcated into Oral Therapy, and Intravesical Therapy. Oral Therapy accounted for the largest market share of 56.96% in 2020, with a market value of USD 674.05 Million, and is projected to grow at a CAGR of 4.44% during the forecast period. Intravesical Therapy was the second-largest market in 2020, valued at USD 509.25 Million in 2020.

Interstitial Cystitis Drugs Market, By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on the Sales Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies accounted for the largest market share of 67.69% in 2020, with a market value of USD 800.99 Million, and is projected to grow at a CAGR of 4.52% during the forecast period. Retail Pharmacies were the second-largest market in 2020, valued at USD 309.48 Million in 2020.

Interstitial Cystitis Drugs Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Players

The "Global Interstitial Cystitis Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Johnson & Johnson, Kyorin Pharmaceutical, UCB Pharma, Astellas Pharma, Bayer, Eli Lilly, Lipella Pharmaceuticals, Seikagaku Corporation, and Grunenthal. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In January 2021, The Ministry of Health, Labour and Welfare (hereinafter "MHLW") had given Kyorin Pharmaceutical Co., Ltd. permission to market interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso") in Japan. Kyorin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of KYORIN Holdings, Inc.
  • In April 2021: Kyorin Pharmaceutical Co., Ltd. a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso").
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Interstitial Cystitis Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in Global Interstitial Cystitis Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW

3 EXECUTIVE SUMMARY

  • 3.1 MARKET OVERVIEW
  • 3.2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE (USD MILLION)
  • 3.4 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
  • 3.5 FUTURE MARKET OPPORTUNITIES
  • 3.6 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 MARKET DRIVERS
    • 4.1.1 HIGH PREVALENCE OF INTERSTITIAL CYSTITIS IN THE US
    • 4.1.2 RESEARCH ACTIVITY ON A RISE
  • 4.2 MARKET RESTRAINTS
    • 4.2.1 LACK OF AWARENESS AMONG CONSUMERS, LIMITED DRUG APPROVAL, AND HIGH-COST TREATMENT
  • 4.3 MARKET OPPORTUNITIES
    • 4.3.1 EMERGENCE OF INNOVATIVE TREATMENT OPTIONS SUCH AS REGENERATIVE THERAPY AND GENE THERAPY
  • 4.4 IMPACT OF COVID -19 ON GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • 4.1 PORTER'S FIVE FORCES ANALYSIS
  • 4.2 PRODUCT LIFELINE

5 MARKET, BY TYPE

  • 5.1 OVERVIEW
  • 5.2 ORAL THERAPY
  • 5.3 INTRAVESICAL THERAPY

6 MARKET, BY SALES CHANNEL

  • 6.1 OVERVIEW
  • 6.2 HOSPITAL PHARMACIES
  • 6.3 RETAIL PHARMACIES USES
  • 6.4 ONLINE PHARMACIES

7 MARKET, BY GEOGRAPHY

  • 7.1 OVERVIEW
  • 7.2 NORTH AMERICA
    • 7.2.1 THE U.S.
    • 7.2.2 CANADA
    • 7.2.3 MEXICO
  • 7.3 EUROPE
    • 7.3.1 GERMANY
    • 7.3.2 FRANCE
    • 7.3.3 U.K.
    • 7.3.4 REST OF EUROPE
  • 7.4 ASIA PACIFIC
    • 7.4.1 JAPAN
    • 7.4.2 CHINA
    • 7.4.3 INDIA
    • 7.4.4 REST OF ASIA PACIFIC
  • 7.5 ROW
    • 7.5.1 MIDDLE EAST AND AFRICA
    • 7.5.2 LATIN AMERICA

8 COMPETITIVE LANDSCAPE

  • 8.1 OVERVIEW
  • 8.2 COMPETITIVE SCENARIO
  • 8.3 COMPANY MARKET RANKING ANALYSIS

9 COMPANY PROFILES

  • 9.1 PFIZER INC.
    • 9.1.1 COMPANY OVERVIEW
    • 9.1.2 COMPANY INSIGHTS
    • 9.1.3 PRODUCT BENCHMARKING
    • 9.1.4 KEY DEVELOPMENT
    • 9.1.5 SWOT ANALYSIS
  • 9.2 JOHNSON & JOHNSON
    • 9.2.1 COMPANY OVERVIEW
    • 9.2.2 COMPANY INSIGHTS
    • 9.2.3 SEGMENT BREAKDOWN
    • 9.2.4 PRODUCT BENCHMARKING
    • 9.2.5 SWOT ANALYSIS
  • 9.3 KYORIN PHARMACEUTICAL
    • 9.3.1 COMPANY OVERVIEW
    • 9.3.2 COMPANY INSIGHTS
    • 9.3.3 SEGMENT BREAKDOWN
    • 9.3.4 PRODUCT BENCHMARKING
    • 9.3.5 KEY DEVELOPMENT
    • 9.3.6 SWOT ANALYSIS
  • 9.4 UCB PHARMA
    • 9.4.1 COMPANY OVERVIEW
    • 9.4.2 COMPANY INSIGHTS
    • 9.4.3 SEGMENT BREAKDOWN
    • 9.4.4 PRODUCT BENCHMARKING
    • 9.4.5 KEY DEVELOPMENT
    • 9.4.6 SWOT ANALYSIS
  • 9.5 ASTELLAS PHARMA
    • 9.5.1 COMPANY OVERVIEW
    • 9.5.2 COMPANY INSIGHTS
    • 9.5.3 SEGMENT BREAKDOWN
    • 9.5.4 PRODUCT BENCHMARKING
    • 9.5.5 SWOT ANALYSIS
  • 9.6 ELI LILLY AND COMPANY
    • 9.6.1 COMPANY OVERVIEW
    • 9.6.2 COMPANY INSIGHTS
    • 9.6.3 SEGMENT BREAKDOWN
    • 9.6.4 PRODUCT BENCHMARKING
    • 9.6.5 KEY DEVELOPMENT
  • 9.7 BAYER AG
    • 9.7.1 COMPANY OVERVIEW
    • 9.7.2 COMPANY INSIGHTS
    • 9.7.3 SEGMENT BREAKDOWN
    • 9.7.4 PRODUCT BENCHMARKING
    • 9.7.5 KEY DEVELOPMENT
  • 9.8 LIPELLA PHARMACEUTICALS
    • 9.8.1 COMPANY OVERVIEW
    • 9.8.2 COMPANY INSIGHTS
    • 9.8.3 PRODUCT BENCHMARKING
  • 9.9 SEIKAGAKU CORPORATION
    • 9.9.1 COMPANY OVERVIEW
    • 9.9.2 COMPANY INSIGHTS
    • 9.9.3 SEGMENT BREAKDOWN
    • 9.9.4 PRODUCT BENCHMARKING
    • 9.9.5 KEY DEVELOPMENT
  • 9.10 GRUNENTHAL
    • 9.10.1 COMPANY OVERVIEW
    • 9.10.2 COMPANY INSIGHTS
    • 9.10.3 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY GEOGRAPHY, 2021 - 2028 (USD MILLION)
  • TABLE 4 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 6 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 7 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 8 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 9 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE10 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE11 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE12 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE13 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE14 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE15 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE16 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE17 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE18 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE19 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 20 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 21 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 22 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 23 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 24 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 25 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 26 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 27 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 28 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 29 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 30 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 31 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 32 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 33 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 34 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 35 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
  • TABLE 36 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 37 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 38 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 39 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 40 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
  • TABLE 41 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
  • TABLE 42 COMPANY MARKET RANKING ANALYSIS
  • TABLE 43 PFIZER INC.: PRODUCT BENCHMARKING
  • TABLE 44 PFIZER INC.: KEY DEVELOPMENT
  • TABLE 45 JOHNSON & JOHNSON: PRODUCT BENCHMARKING
  • TABLE 46 KYORIN PHARMACEUTICAL: PRODUCT BENCHMARKING
  • TABLE 47 KYORIN PHARMACEUTICAL: KEY DEVELOPMENT
  • TABLE 48 UCB PHARMA: PRODUCT BENCHMARKING
  • TABLE 49 UCB PHARMA: KEY DEVELOPMENT
  • TABLE 50 ASTELLAS PHARMA: PRODUCT BENCHMARKING
  • TABLE 51 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
  • TABLE 52 ELI LILLY AND COMPANY: KEY DEVELOPMENT
  • TABLE 53 BAYER AG: PRODUCT BENCHMARKING
  • TABLE 54 BAYER AG: KEY DEVELOPMENT
  • TABLE 55 LIPELLA PHARMACEUTICALS: PRODUCT BENCHMARKING
  • TABLE 56 SEIKAGAKU CORPORATION: PRODUCT BENCHMARKING
  • TABLE 57 SEIKAGAKU CORPORATION: KEY DEVELOPMENT
  • TABLE 58 GRUNENTHAL: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET OVERVIEW
  • FIGURE 6 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
  • FIGURE 7 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE USD MILLION)
  • FIGURE 8 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE10 NORTH AMERICA DOMINATED THE MARKET IN 2020
  • FIGURE11 MARKET OVERVIEW
  • FIGURE12 PORTER'S FIVE FORCES ANALYSIS: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • FIGURE13 PRODUCT LIFELINE: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
  • FIGURE14 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE
  • FIGURE15 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL
  • FIGURE16 COMPOUND ANNUAL GROWTH RATE OF MARKET IN PROMINENT COUNTRIES ACROSS THE GLOBE
  • FIGURE17 NORTH AMERICA MARKET SNAPSHOT
  • FIGURE18 THE U.S. MARKET SNAPSHOT
  • FIGURE19 CANADA MARKET SNAPSHOT
  • FIGURE 20 MEXICO MARKET SNAPSHOT
  • FIGURE 21 EUROPE MARKET SNAPSHOT
  • FIGURE 22 GERMANY MARKET SNAPSHOT
  • FIGURE 23 FRANCE MARKET SNAPSHOT
  • FIGURE 24 U.K. MARKET SNAPSHOT
  • FIGURE 25 ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 26 JAPAN MARKET SNAPSHOT
  • FIGURE 27 CHINA MARKET SNAPSHOT
  • FIGURE 28 INDIA MARKET SNAPSHOT
  • FIGURE 29 ROW SNAPSHOT
  • FIGURE 30 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 31 LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 32 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 33 PFIZER INC.: COMPANY INSIGHT
  • FIGURE 34 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 35 JOHNSON & JOHNSON: COMPANY INSIGHT
  • FIGURE 36 JOHNSON & JOHNSON: BREAKDOWN
  • FIGURE 37 JOHNSON & JOHNSON: SWOT ANALYSIS
  • FIGURE 38 KYORIN PHARMACEUTICAL: COMPANY INSIGHT
  • FIGURE 39 KYORIN PHARMACEUTICAL: BREAKDOWN
  • FIGURE 40 KYORIN PHARMACEUTICAL: SWOT ANALYSIS
  • FIGURE 41 UCB PHARMA: COMPANY INSIGHT
  • FIGURE 42 UCB PHARMA: BREAKDOWN
  • FIGURE 43 UCB PHARMA: SWOT ANALYSIS
  • FIGURE 44 ASTELLAS PHARMA: COMPANY INSIGHT
  • FIGURE 45 ASTELLAS PHARMA: BREAKDOWN
  • FIGURE 46 ASTELLAS PHARMA: SWOT ANALYSIS
  • FIGURE 47 ELI LILLY AND COMPANY: COMPANY INSIGHT
  • FIGURE 48 ELI LILLY AND COMPANY: BREAKDOWN
  • FIGURE 49 BAYER AG: COMPANY INSIGHT
  • FIGURE 50 BAYER AG: BREAKDOWN
  • FIGURE 51 LIPELLA PHARMACEUTICALS: COMPANY INSIGHT
  • FIGURE 52 SEIKAGAKU CORPORATION: COMPANY INSIGHT
  • FIGURE 53 SEIKAGAKU CORPORATION: BREAKDOWN
  • FIGURE 54 GRUNENTHAL: COMPANY INSIGHT